Koyfin Home > Directory > Health Care > Kura Oncology > EBITDA

Kura Oncology EBITDA Chart (KURA)

Kura Oncology annual/quarterly EBITDA from 2015 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Kura Oncology EBITDA for the quarter ending June 06, 2020 was $-21m a 24.94% decrease of -5m year over year
  • Kura Oncology EBITDA for the last 12 months ending June 06, 2020 was $-78m a 18.64% decrease of -15m year over year
  • Kura Oncology Annual EBITDA for 2019 was $-67m a 6.81% decrease of -5m from 2018
  • Kura Oncology Annual EBITDA for 2018 was $-63m a 42.67% decrease of -27m from 2017
  • Kura Oncology Annual EBITDA for 2017 was $-36m a 21.39% decrease of -8m from 2016
Other Income Statement Metrics:
  • Kura Oncology Net Income for the quarter ending December 12, 2018 was $-16m a 9.28% decrease of -1m year over year
View Chart On Koyfin

Quarterly KURA EBITDA Data

06/2020$-21m
12/2019$-19m
09/2019$-18m
06/2019$-16m
03/2019$-15m
12/2018$-17m
09/2018$-16m
06/2018$-15m
03/2018$-15m
12/2017$-11m

Annual KURA EBITDA Data

2019$-67m
2018$-63m
2017$-36m
2016$-28m
2015$-24m
2014$-12m